Penumbra Inc. ((PEN)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Penumbra Inc. is conducting a study titled ‘BOLT: A Prospective, Multicenter Study of Patients With Deep Vein Thrombosis to Evaluate the Safety and Efficacy of the Indigo® Aspiration System.’ The study aims to assess the safety and efficacy of the Indigo Aspiration System for treating deep vein thrombosis (DVT), a condition characterized by blood clots in deep veins, which can lead to serious health complications.
Intervention/Treatment: The study tests the Indigo Aspiration System, a medical device designed for percutaneous mechanical thrombectomy. This device aims to remove blood clots in patients suffering from DVT, potentially offering a safer and more effective treatment option.
Study Design: This interventional study employs a single-group model without masking, focusing on treatment as its primary purpose. All participants receive the same intervention, allowing researchers to directly observe the effects of the Indigo Aspiration System on DVT.
Study Timeline: The study began on August 4, 2021, with the last update submitted on July 14, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results, which are yet to be submitted.
Market Implications: The ongoing study could significantly impact Penumbra Inc.’s stock performance, as positive results may enhance investor confidence and position the company as a leader in DVT treatment. This development could also influence the competitive landscape, prompting responses from other companies in the medical device industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.